Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 4, 2009, Pages 837-845

  Attia, Sabry M ^a,b   Al Anteet, Alaa A ^a   Al Rasheed, Nouf M ^a   Alhaider, Abdulqader A ^a   Al Harbi, Mohammed M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

Author keywords

Carcinogenicity; Chromosomal aberrations; Dexrazoxane; Etoposide; Micronuclei; Mitotic activity

Indexed keywords

BIOCHEMICAL MARKER; CYCLOPHOSPHAMIDE; ETOPOSIDE; GLUTATHIONE; RAZOXANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; ERYTHROBLAST; GENOTOXICITY; INTERPHASE; LIPID PEROXIDATION; MALE; METAPHASE; MICRONUCLEUS; MITOSIS RATE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SCORING SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CHROMOSOME ABERRATIONS; ETOPOSIDE; GLUTATHIONE; LIPID PEROXIDATION; MALE; MICE; MICRONUCLEUS TESTS; OXIDATIVE STRESS; RAZOXANE;

EID: 68149183617     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0934-8     Document Type: Article

References (45)

1. Adler ID (1984) Cytogenetic tests in mammals. In: Venitt S, Parry JM (eds) Mutagenicity testing: a practical approach. IRL Press, Oxford, pp 275-306
2. K Agarwal A Mukherjee S Sen 1994 Etoposide (VP-16): cytogenetic studies in mice Environ Mol Mutagen 23 3 190 193
3. T Andoh R Ishida 1998 Catalytic inhibitors of DNA topoisomerase II Biochim Biophys Acta 1400 155 171
4. J Ashby H Tinwell P Glover 1994 Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses Environ Mol Mutagen 24 51 60
5. SM Attia 2008 Abatement by naringin of lomefloxacin-induced genomic instability in mice Mutagenesis 23 6 515 521
6. SM Attia U Kliesch G Schriever-Schwemmer 2003 Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe Environ Mol Mutagen 41 99 103
7. SM Attia TE Schmid OA Badary 2002 Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors Mutat Res 520 1 13
8. G Boos H Stopper 2000 Genotoxicity of several clinically used topoisomerase II inhibitors Toxicol Lett 116 1-2 7 16
9. M Chen WT Beck 1995 Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26 Cancer Res 55 1509 1516
10. RC Choudhury AK Palo PJ Sahu 2004 Cytogenetic risk assessment of etoposide from mouse bone marrow Appl Toxicol 24 115 122
11. A Cierniak M Papiez M Kapiszewska 2004 Modulatory effect of quercetin on DNA damage, induced by etoposide in bone marrow cells and on changes in the activity of antioxidant enzymes in rats Rocz Akad Med Bialymst 49 Suppl. 1 167 169
12. FH Drake GA Hofmann SM Mong 1989 In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone Cancer Res 49 10 2578 2583
13. GL Ellman 1959 Tissue sulfhydryl groups Arch Biochem Biophys 74 214 226
14. CA Felix 2001 Leukemias related to treatment with DNA topoisomerase II inhibitors Med Pediatr Oncol 36 5 525 535
15. KR Hande 1998 Etoposide: four decades of development of a topoisomerase II inhibitor Eur J Cancer 34 10 1514 1521
16. BB Hasinoff TI Kuschak JC Yalowich 1995 A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane) Biochem Pharmacol 50 953 958
17. BB Hasinoff JC Yalowich Y Ling 1996 The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin mediated growth inhibition of Chinese hamster ovary cells Anticancer Drugs 7 558 567
18. KF Hofland AV Thougaard M Dejligbjerg 2005 Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors Clin Cancer Res 11 18 6722 6729
19. KF Hofland V Thougaard M Sehested 2005 Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin Cancer Res 11 3915 3924
20. B Holm PB Jensen M Sehested 1996 ICRF-187 rescue in etoposid treatment in vivo. A model targeting high dose topoisomerase II poisons to CNS tumors Cancer Chemother Pharmacol 38 203 209
21. R Humeniuk L Kaczmarek W Peczynska-Czoch 2003 Cytotoxicity and cell cycle effects of novel indolo[2, 3-b]quinoline derivatives Oncol Res 13 5 269 277
22. VE Kagan AI Kuzmenko YY Tyurina 2001 Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase Cancer Res 61 7777 7784
23. VE Kagan JC Yalowich GG Borisenko 1999 Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach Mol Pharmacol 56 494 506
24. H Kaiserová GJ den Hartog T Simůnek 2006 Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin Br J Pharmacol 149 7 920 930
25. M Kapiszewska A Cierniak M Elas 2007 Lifespan of etoposide-treated human neutrophils is affected by antioxidant ability of quercetin Toxicol In Vitro 21 6 1020 1030
26. M Kapiszewska A Cierniak MA Papiez 2007 Prolonged quercetin administration diminishes the etopoide-induced DAN damage in bone marrow cells of rats Drug Chem Toxicol 30 67 81
27. SW Langer M Sehested PB Jensen 2001 Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice Ann Oncol 12 405 410
28. D Lebrecht A Geist UP Ketelsen 2007 Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats Br J Pharmacol 151 6 771 778
29. OM Lowry NJ Rosebrough AL Fare 1951 Protein measurement with Folin phenol reagent J Biol Chem 193 265 275
30. G Minotti P Menna E Salvatorelli 2004 Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 185 229
31. YY Mo WT Beck 1999 DNA damage signals induction of Fas ligand in tumor cells Mol Pharmacol 55 216 222
32. H Ohkawa N Ohishi K Yagi 1979 Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction Anal Biochem 95 351 358
33. M Pearlman D Jendiroba L Pagliaro 2003 Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines Leuk Res 27 617 626
34. M Pearlman D Jendiroba L Pagliaro 2003 Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity Cancer Chemother Pharmacol 52 477 481
35. VB Ritov R Goldman DA Stoyanovsky 1995 Antioxidant paradoxes of phenolic compounds: peroxyl radical scavenger and lipid antioxidant, etoposide (VP-16), inhibits sarcoplasmic reticulum Ca(2+)-ATPase via thiol oxidation by its phenoxyl radical Arch Biochem Biophys 321 140 152
36. M Sehested PB Jensen BS Sørensen 1993 Antagonistic effect of the cardioprotector (+)-1, 2-bis(3, 5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16) Biochem Pharmacol 46 3 389 393
37. T Siitonen P Alaruikka P Mantymaa 1999 Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposide-induced oxidative stress Ann Oncol 10 1361 1367
38. PJ Smith S Soués T Gottlieb 1994 Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells Br J Cancer 70 914 921
39. SM Swain P Vici 2004 The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review J Cancer Res Clin Oncol 130 1 7
40. SM Swain F Whaley MC Gerber 1997 Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy J Clin Oncol 15 1333 1340 (Pubitemid 27167364)
41. Z Topcu 2001 DNA topoisomerases as targets for anticancer drugs J Clin Pharm Ther 26 405 416
42. SD Turner SW Wijnhoven H Tinwell 2001 Assays to predict the genotoxicity of the chromosomal mutagen etoposide-focussing on the best assay Mutat Res 493 1-2 139 147
43. JC Wang 1996 DNA topoisomerases Annu Rev Biochem 65 635 692
44. L Wang DA Eastmond 2002 Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187 Environ Mol Mutagen 39 4 348 356
45. T Zima V Tesar J Crkovská 1998 ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats Nephrol Dial Transplant 13 8 1975 1979